Imagine a flashlight that only lights up when you're near a road sign: that's roughly how drug discovery works when scientists follow genetic clues. A team of researchers examined over 26,000 target-disease pairs: combinations of a protein that a drug acts on and the disease it treats. If a target has any genetic link to the disease, the odds of success multiply severalfold.
But a genetic trace alone isn't a magic wand. When the authors tried to predict success using only genetics, accuracy was low. Analyzing scientific publications worked best, but that likely just picks up already known facts rather than foreseeing new discoveries. Genetics lights the way but doesn't replace the long, painstaking validation process.
Still, the study offers a practical guide. The researchers compiled a list of 1,433 target-disease pairs that are already in early trials and have genetic backing. It's a sort of treasure map for pharmacologists — not a guarantee of gold, but a hint of where to dig first.
Even without genetics, random drug discovery yields some results. But adding genetic data boosts the chances by about one percentage point — seems trivial, but for patients with rare diseases, it can be decisive.